Literature DB >> 31709908

Metabolic Remodeling Promotes Cardiac Hypertrophy by Directing Glucose to Aspartate Biosynthesis.

Julia Ritterhoff1, Sara Young1, Outi Villet1, Dan Shao1, F Carnevale Neto2, Lisa F Bettcher2, Yun-Wei A Hsu1, Stephen C Kolwicz1, Daniel Raftery2, Rong Tian1.   

Abstract

RATIONALE: Hypertrophied hearts switch from mainly using fatty acids (FAs) to an increased reliance on glucose for energy production. It has been shown that preserving FA oxidation (FAO) prevents the pathological shift of substrate preference, preserves cardiac function and energetics, and reduces cardiomyocyte hypertrophy during cardiac stresses. However, it remains elusive whether substrate metabolism regulates cardiomyocyte hypertrophy directly or via a secondary effect of improving cardiac energetics.
OBJECTIVE: The goal of this study was to determine the mechanisms of how preservation of FAO prevents the hypertrophic growth of cardiomyocytes. METHODS AND
RESULTS: We cultured adult rat cardiomyocytes in a medium containing glucose and mixed-chain FAs and induced pathological hypertrophy by phenylephrine. Phenylephrine-induced hypertrophy was associated with increased glucose consumption and higher intracellular aspartate levels, resulting in increased synthesis of nucleotides, RNA, and proteins. These changes could be prevented by increasing FAO via deletion of ACC2 (acetyl-CoA-carboxylase 2) in phenylephrine-stimulated cardiomyocytes and in pressure overload-induced cardiac hypertrophy in vivo. Furthermore, aspartate supplementation was sufficient to reverse the antihypertrophic effect of ACC2 deletion demonstrating a causal role of elevated aspartate level in cardiomyocyte hypertrophy. 15N and 13C stable isotope tracing revealed that glucose but not glutamine contributed to increased biosynthesis of aspartate, which supplied nitrogen for nucleotide synthesis during cardiomyocyte hypertrophy.
CONCLUSIONS: Our data show that increased glucose consumption is required to support aspartate synthesis that drives the increase of biomass during cardiac hypertrophy. Preservation of FAO prevents the shift of metabolic flux into the anabolic pathway and maintains catabolic metabolism for energy production, thus preventing cardiac hypertrophy and improving myocardial energetics.

Entities:  

Keywords:  aspartic acid; cardiomyocyte; glucose; hypertrophy; metabolism; nucleotides

Mesh:

Substances:

Year:  2019        PMID: 31709908     DOI: 10.1161/CIRCRESAHA.119.315483

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  45 in total

1.  Fueling Cardiac Hypertrophy.

Authors:  Timothy R Matsuura; Teresa C Leone; Daniel P Kelly
Journal:  Circ Res       Date:  2020-01-16       Impact factor: 17.367

2.  Small molecule QF84139 ameliorates cardiac hypertrophy via activating the AMPK signaling pathway.

Authors:  Xu-Xia Li; Peng Zhang; Yang Yang; Jing-Jing Wang; Yan-Jun Zheng; Ji-Liang Tan; Shen-Yan Liu; Yong-Ming Yan; You-Yi Zhang; Yong-Xian Cheng; Huang-Tian Yang
Journal:  Acta Pharmacol Sin       Date:  2021-05-09       Impact factor: 6.150

Review 3.  Cardiac Energy Metabolism in Heart Failure.

Authors:  Gary D Lopaschuk; Qutuba G Karwi; Rong Tian; Adam R Wende; E Dale Abel
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

Review 4.  Considerations for using isolated cell systems to understand cardiac metabolism and biology.

Authors:  Lindsey A McNally; Tariq R Altamimi; Kyle Fulghum; Bradford G Hill
Journal:  J Mol Cell Cardiol       Date:  2020-12-21       Impact factor: 5.000

5.  The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure.

Authors:  Ahmad A Cluntun; Rachit Badolia; Sandra Lettlova; K Mark Parnell; Thirupura S Shankar; Nikolaos A Diakos; Kristofor A Olson; Iosif Taleb; Sean M Tatum; Jordan A Berg; Corey N Cunningham; Tyler Van Ry; Alex J Bott; Aspasia Thodou Krokidi; Sarah Fogarty; Sophia Skedros; Wojciech I Swiatek; Xuejing Yu; Bai Luo; Shannon Merx; Sutip Navankasattusas; James E Cox; Gregory S Ducker; William L Holland; Stephen H McKellar; Jared Rutter; Stavros G Drakos
Journal:  Cell Metab       Date:  2020-12-16       Impact factor: 27.287

6.  Mitochondria in Pathological Cardiac Remodeling.

Authors:  Michael P Lazaropoulos; John W Elrod
Journal:  Curr Opin Physiol       Date:  2022-02-19

7.  Cardiac Pressure Overload Decreases ETV1 Expression in the Left Atrium, Contributing to Atrial Electrical and Structural Remodeling.

Authors:  Naoko Yamaguchi; Junhua Xiao; Deven Narke; Devin Shaheen; Xianming Lin; Erik Offerman; Alireza Khodadadi-Jamayran; Akshay Shekhar; Alex Choy; Sojin Y Wass; David R Van Wagoner; Mina K Chung; David S Park
Journal:  Circulation       Date:  2020-11-23       Impact factor: 29.690

Review 8.  PPAR control of metabolism and cardiovascular functions.

Authors:  David Montaigne; Laura Butruille; Bart Staels
Journal:  Nat Rev Cardiol       Date:  2021-06-14       Impact factor: 32.419

9.  Dual-specificity Phosphatase 9 protects against Cardiac Hypertrophy by targeting ASK1.

Authors:  Lang Jiang; Lingyun Ren; Xin Guo; Jing Zhao; Hao Zhang; Shanshan Chen; Sheng Le; Hao Liu; Ping Ye; Manhua Chen; Jiahong Xia
Journal:  Int J Biol Sci       Date:  2021-05-27       Impact factor: 6.580

10.  Nutritional modulation of heart failure in mitochondrial pyruvate carrier-deficient mice.

Authors:  Kyle S McCommis; Attila Kovacs; Carla J Weinheimer; Trevor M Shew; Timothy R Koves; Olga R Ilkayeva; Dakota R Kamm; Kelly D Pyles; M Todd King; Richard L Veech; Brian J DeBosch; Deborah M Muoio; Richard W Gross; Brian N Finck
Journal:  Nat Metab       Date:  2020-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.